Skip to content

News Releases

Date Title and Summary Additional Formats
Toggle Summary Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO , Nov. 20, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the closing of its previously announced underwritten public offering of 2,938,986 shares of its common stock at a public offering price of $13.00 per share.
View HTML
Toggle Summary Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
SAN DIEGO , Nov. 16, 2017 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the pricing of an underwritten public offering of 2,015,901 shares of its common stock at a price to the public of $13.00 per share. In addition, and in lieu of common stock, Mirati is offering to
View HTML
Toggle Summary Mirati Therapeutics Announces Proposed Public Offering Of Common Stock
SAN DIEGO , Nov. 15, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock. Mirati expects to grant the underwriters a 30-day option to purchase up to an additional 15% of
View HTML
Toggle Summary Mirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And KRAS Inhibitor Programs
- Sitravatinib immuno-oncology program to be accelerated following encouraging clinical efficacy data previously reported for sitravatinib in combination with nivolumab - KRAS program advances with orally-active, mutation-selective clinical lead and backups; IND submission anticipated in 2018 -
View HTML
Toggle Summary Mirati Therapeutics Reports Third Quarter 2017 Financial Results
SAN DIEGO , Nov. 1, 2017 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage oncology biotechnology company, reported financial results for the third quarter 2017. "We are excited by the momentum we have created in our programs, including the sitravatinib program as both a
View HTML
Toggle Summary Mirati Therapeutics' Mocetinostat Included In Stand Up To Cancer's Cutting-Edge Clinical Trial Initiative For NSCLC Patients
· Clinical trial combining mocetinostat with pembrolizumab and guadecitabine in NSCLC now open and enrolling patients · Enrollment continues in Mirati-sponsored clinical trial of mocetinostat combined with durvalumab in checkpoint refractory NSCLC; first cohort expands to stage 2. SAN DIEGO , Oct.
View HTML
Toggle Summary Mirati Therapeutics To Present At Upcoming Healthcare Conferences
SAN DIEGO , Sept. 19, 2017 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology biotechnology company, will present at the 2017 Cantor Fitzgerald Global Healthcare Conference in New York on Tuesday, September 26 th at 1:40 p.m. ET / 10:40 a.m. PT .
View HTML
Toggle Summary Mirati Therapeutics Presents Positive Preliminary Data From On-Going Clinical Trials Of Sitravatinib In Non-Small Cell Lung Cancer
- Combination of sitravatinib and nivolumab in NSCLC patients with documented progression following checkpoint therapy demonstrated 3 confirmed Partial Responses in first 11 evaluable patients - First evaluable NSCLC patient with CBL inactivating mutation treated with single agent sitravatinib
View HTML
Toggle Summary Sitravatinib Data To Be Highlighted At The IASLC 18th World Conference on Lung Cancer
SAN DIEGO , Sept. 6, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology biotechnology company, will highlight data on sitravatinib at the IASLC 18th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in
View HTML
Toggle Summary Mirati Therapeutics To Participate In Immuno-Oncology Panel Discussion At The 2017 Citi Biotech Conference
SAN DIEGO , Aug. 30, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology biotechnology company, will participate in a panel discussion, "I/O Beyond PD-1: Opportunities & Challenges" at the 2017 Citi Biotech Conference in Boston on Wednesday, September 6
View HTML